GlassScriptPhysician profile
Thuan Nguyen
NPI 1659421535
$78,009.86
in general payments reported to CMS, 2019-2025
26 companies · $7,322 in 2025
The $7,322 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,938 · 2021: $5,466 · 2022: $8,511 · 2023: $17K · 2024: $19K · 2025: $7,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $3,514 · Food and Beverage: $3,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,132.00 |
| Travel and Lodging | $3,514.43 |
| Food and Beverage | $3,075.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $74,388.70 | 2019-2025 | Vemlidy, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.50 | 2019-2023 | Trulance |
| Mentor Worldwide LLC | $442.16 | 2019-2022 | |
| Redhill Biopharma INC. | $400.04 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $370.56 | 2019-2024 | Linzess |
| Abbvie INC. | $287.98 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.50 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $216.34 | 2024-2025 | Voquezna |
| Allergan, INC. | $151.58 | 2019-2020 | |
| Novo Nordisk INC | $132.75 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Biotronik Nro, INC. | $129.14 | 2025 | Prospera |
| Nestle Healthcare Nutrition INC. | $117.90 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $93.05 | 2020-2021 | |
| Evoke Pharma, INC. | $81.76 | 2021-2022 | |
| Boston Scientific Corporation | $67.78 | 2022-2024 | Rotatable Snare |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.98 | 2023-2025 | |
| Alfasigma USA, INC. | $48.53 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $43.49 | 2019-2020 | |
| Lilly USA, LLC | $40.45 | 2019-2021 | |
| Ardelyx, INC. | $25.79 | 2022 | |
| Exelixis INC. | $25.22 | 2023 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $20.95 | 2019 | |
| Capsovision, INC. | $19.00 | 2025 | Capsocam Plus |
| Madrigal Pharmaceuticals | $16.97 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $14.77 | 2020 | |
| Eisai INC. | $13.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuan Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.